Symbols / BJDX $1.95 +2.63%
BJDX Chart
About
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 1.90M |
| Enterprise Value | -3.14M | Income | -6.85M | Sales | — |
| Book/sh | 9.88 | Cash/sh | 5.31 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6 | IPO | — |
| P/E | 0.00 | Forward P/E | -6.09 | PEG | — |
| P/S | — | P/B | 0.20 | P/C | — |
| EV/EBITDA | 0.46 | EV/Sales | — | Quick Ratio | 4.62 |
| Current Ratio | 4.88 | Debt/Eq | 2.17 | LT Debt/Eq | — |
| EPS (ttm) | -15.25 | EPS next Y | -0.32 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2024-03-28 17:00 | ROA | -62.76% |
| ROE | -117.02% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 972.22K |
| Shs Float | 844.44K | Short Float | 3.82% | Short Ratio | 0.08 |
| Short Interest | — | 52W High | 40.80 | 52W Low | 1.70 |
| Beta | 0.72 | Avg Volume | 241.13K | Volume | 11.42K |
| Target Price | — | Recom | None | Prev Close | $1.90 |
| Price | $1.95 | Change | 2.63% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.95
Latest analyst target
3. DCF / Fair value
$-68.62
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.95
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-08-03 | down | Dawson James | Buy → Neutral | — |
- Bluejay’s 20-minute sepsis test drives 2026 plan and $20M cash goal - Stock Titan Fri, 06 Mar 2026 11
- Bluejay Diagnostics sends response letter to NorthStrive Fund II LP - Investing.com Mon, 16 Mar 2026 10
- Bluejay Weighs Proposed Therapeutic Acquisition, Reaffirms Symphony Focus - TipRanks Mon, 16 Mar 2026 10
- Bluejay Diagnostics Stock Plummets 37% With 11-Day Losing Streak - Trefis ue, 23 Dec 2025 08
- Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split - Yahoo Finance ue, 27 Jan 2026 08
- Sepsis test maker builds supply for 10M rapid kits as key trial advances - Stock Titan ue, 17 Feb 2026 08
- Bluejay Diagnostics Announces Full Exercise of Prefunded Warrants and Current Share Structure Update - Quiver Quantitative Fri, 20 Feb 2026 08
- Bluejay Diagnostics Inc. (BJDX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade hu, 09 Oct 2025 14
- Bluejay Diagnostics says all prefunded warrants exercised; ~972,000 shares outstanding, 1.5M cash-exercise warrants - TradingView Fri, 20 Feb 2026 08
- Bluejay Diagnostics (BJDX) Stock Rockets on Expanded Partnership: A Game-Changer for Sepsis Testing? - RagingBull hu, 09 Oct 2025 07
- Medical diagnostics company Bluejay Diagnostics Inc (stock code: BJDX) is facing financial pressure. According to the company's latest disclosed financial plan, in order to maintain normal operations and advance R&D projects, it must secure at least $20 milli - Bitget hu, 05 Mar 2026 19
- Why Is Bluejay Diagnostics Stock (BJDX) Up 115% Today? - TipRanks hu, 09 Oct 2025 07
- Bluejay Diagnostics stock soars after expanding manufacturing partnership - Investing.com hu, 09 Oct 2025 07
- $4.5M raise: Bluejay Diagnostics secures private placement to fund FDA approval work - Stock Titan hu, 09 Oct 2025 07
- Bluejay Diagnostics Advances Clinical Milestones and Financial Initiatives, Reaches 50% Enrollment in SYMON-II Trial - Quiver Quantitative Mon, 10 Nov 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -6.70M | -9.17M | -8.77M | -2.98M |
| TotalUnusualItems | 0.00 | -237.31K | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -237.31K | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.72M | -9.95M | -9.30M | -3.49M |
| ReconciledDepreciation | 199.10K | 780.96K | 306.37K | 145.72K |
| ReconciledCostOfRevenue | 0.00 | 200.13K | 0.00 | |
| EBITDA | -6.70M | -9.17M | -9.01M | -2.98M |
| EBIT | -6.89M | -9.95M | -9.32M | -3.12M |
| NetInterestIncome | -677.21K | 164.90K | 89.67K | -367.46K |
| InterestExpense | 823.03K | 0.00 | 0.00 | 367.46K |
| InterestIncome | 145.82K | 164.90K | 89.67K | |
| NormalizedIncome | -7.72M | -9.95M | -9.06M | -3.49M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.72M | -9.95M | -9.30M | -3.49M |
| TotalExpenses | 7.17M | 10.31M | 9.57M | 3.16M |
| TotalOperatingIncomeAsReported | -7.17M | -10.31M | -9.32M | -3.23M |
| DilutedAverageShares | 45.85K | 774.00 | 631.00 | 628.00 |
| BasicAverageShares | 45.85K | 774.00 | 631.00 | 628.00 |
| DilutedEPS | -456.76 | -12.86K | -14.73K | -5.55K |
| BasicEPS | -456.76 | -12.86K | -14.73K | -5.55K |
| DilutedNIAvailtoComStockholders | -20.94M | -9.95M | -9.30M | -3.49M |
| NetIncomeCommonStockholders | -20.94M | -9.95M | -9.30M | -3.49M |
| OtherunderPreferredStockDividend | 13.22M | 0.00 | ||
| NetIncome | -7.72M | -9.95M | -9.30M | -3.49M |
| NetIncomeIncludingNoncontrollingInterests | -7.72M | -9.95M | -9.30M | -3.49M |
| NetIncomeContinuousOperations | -7.72M | -9.95M | -9.30M | -3.49M |
| PretaxIncome | -7.72M | -9.95M | -9.30M | -3.49M |
| OtherIncomeExpense | 129.03K | 192.43K | -68.84K | 34.32K |
| OtherNonOperatingIncomeExpenses | 129.03K | 192.43K | 168.46K | 34.32K |
| SpecialIncomeCharges | 0.00 | -237.31K | 0.00 | |
| OtherSpecialCharges | -5.00K | |||
| ImpairmentOfCapitalAssets | 0.00 | 237.31K | 0.00 | |
| GainOnSaleOfSecurity | 9.68K | |||
| NetNonOperatingInterestIncomeExpense | -677.21K | 164.90K | 89.67K | -367.46K |
| InterestExpenseNonOperating | 823.03K | 0.00 | 0.00 | 367.46K |
| InterestIncomeNonOperating | 145.82K | 164.90K | 89.67K | |
| OperatingIncome | -7.17M | -10.31M | -9.32M | -3.16M |
| OperatingExpense | 7.17M | 10.31M | 9.37M | 3.16M |
| OtherOperatingExpenses | -75.00K | |||
| ResearchAndDevelopment | 3.47M | 5.71M | 4.15M | 1.15M |
| SellingGeneralAndAdministration | 3.70M | 4.60M | 5.21M | 2.08M |
| SellingAndMarketingExpense | 8.30K | 283.44K | 451.42K | 289.73K |
| GeneralAndAdministrativeExpense | 3.69M | 4.31M | 4.76M | 1.79M |
| OtherGandA | 3.69M | 4.31M | 4.76M | 1.79M |
| GrossProfit | 0.00 | 48.91K | 0.00 | |
| CostOfRevenue | 0.00 | 200.13K | 0.00 | |
| TotalRevenue | 0.00 | 0.00 | 249.04K | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 249.04K | 0.00 |
| Line Item | 2022-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 138.50K | 774.00 | 631.00 | 628.00 |
| ShareIssued | 138.50K | 774.00 | 631.00 | 628.00 |
| TotalDebt | 222.25K | 352.98K | 492.62K | 0.00 |
| TangibleBookValue | 5.73M | 2.89M | 11.54M | 20.38M |
| InvestedCapital | 5.73M | 2.89M | 11.54M | 20.38M |
| WorkingCapital | 4.09M | 1.45M | 10.15M | 20.02M |
| NetTangibleAssets | 5.73M | 2.89M | 11.54M | 20.38M |
| CapitalLeaseObligations | 222.25K | 352.98K | 492.62K | 0.00 |
| CommonStockEquity | 5.73M | 2.89M | 11.54M | 20.38M |
| TotalCapitalization | 5.73M | 2.89M | 11.54M | 20.38M |
| TotalEquityGrossMinorityInterest | 5.73M | 2.89M | 11.54M | 20.38M |
| StockholdersEquity | 5.73M | 2.89M | 11.54M | 20.38M |
| RetainedEarnings | -34.67M | -26.95M | -17.00M | -7.69M |
| AdditionalPaidInCapital | 40.40M | 29.85M | 28.54M | 28.07M |
| CapitalStock | 55.00 | 0.00 | 101.00 | 2.01K |
| CommonStock | 55.00 | 0.00 | 101.00 | 2.01K |
| TotalLiabilitiesNetMinorityInterest | 927.92K | 1.97M | 1.98M | 637.16K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 117.56K | 202.31K | 339.74K | 0.00 |
| OtherNonCurrentLiabilities | 8.57K | 12.32K | 15.82K | |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 108.99K | 189.99K | 323.92K | 0.00 |
| LongTermCapitalLeaseObligation | 108.99K | 189.99K | 323.92K | 0.00 |
| CurrentLiabilities | 810.37K | 1.77M | 1.64M | 637.16K |
| CurrentDebtAndCapitalLeaseObligation | 113.26K | 162.99K | 168.71K | |
| CurrentCapitalLeaseObligation | 113.26K | 162.99K | 168.71K | 0.00 |
| CurrentNotesPayable | 0.00 | |||
| PayablesAndAccruedExpenses | 697.11K | 1.61M | 1.47M | 637.16K |
| CurrentAccruedExpenses | 551.99K | 1.12M | 835.73K | 341.38K |
| Payables | 145.12K | 491.47K | 635.82K | 295.78K |
| DuetoRelatedPartiesCurrent | 2.00K | |||
| AccountsPayable | 145.12K | 491.47K | 635.82K | 295.78K |
| TotalAssets | 6.66M | 4.87M | 13.52M | 21.02M |
| TotalNonCurrentAssets | 1.76M | 1.65M | 1.73M | 358.38K |
| OtherNonCurrentAssets | 35.26K | 28.66K | 35.21K | 21.02K |
| GoodwillAndOtherIntangibleAssets | 4.46K | 4.62K | ||
| OtherIntangibleAssets | 4.46K | 4.62K | ||
| NetPPE | 1.72M | 1.62M | 1.70M | 332.75K |
| AccumulatedDepreciation | -194.95K | -1.24M | -596.41K | -448.84K |
| GrossPPE | 1.92M | 2.86M | 2.29M | 781.58K |
| Leases | 43.23K | 43.23K | 43.23K | 0.00 |
| ConstructionInProgress | 1.35M | 1.05M | 375.47K | 15.08K |
| OtherProperties | 383.06K | 1.62M | 1.73M | 741.59K |
| MachineryFurnitureEquipment | 140.77K | 145.62K | 141.40K | 24.91K |
| BuildingsAndImprovements | 333.27K | 465.51K | ||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 4.90M | 3.22M | 11.79M | 20.66M |
| OtherCurrentAssets | 85.82K | 51.96K | 240.28K | 1.61M |
| CurrentDeferredAssets | 0.00 | 265.08K | 0.00 | |
| PrepaidAssets | 511.12K | 695.30K | 1.43M | 1.61M |
| Inventory | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 4.30M | 2.21M | 10.11M | 19.05M |
| CashAndCashEquivalents | 4.30M | 2.21M | 10.11M | 19.05M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -8.13M | -9.02M | -8.94M | -4.39M |
| RepaymentOfDebt | -2.00M | -4.81K | -801.00 | -298.62K |
| IssuanceOfDebt | 2.00M | 0.00 | 0.00 | 4.50M |
| IssuanceOfCapitalStock | 12.07M | 1.59M | 0.00 | 18.86M |
| CapitalExpenditure | -306.78K | -704.17K | -1.20M | -23.95K |
| InterestPaidSupplementalData | 1.30K | 364.00 | 150.23K | |
| EndCashPosition | 4.30M | 2.21M | 10.11M | 19.05M |
| BeginningCashPosition | 2.21M | 10.11M | 19.05M | 912.36K |
| ChangesInCash | 2.09M | -7.91M | -8.93M | 18.14M |
| FinancingCashFlow | 10.22M | 1.11M | 8.07K | 22.53M |
| CashFlowFromContinuingFinancingActivities | 10.22M | 1.11M | 8.07K | 22.53M |
| NetOtherFinancingCharges | -1.84M | -474.47K | -20.00K | -562.84K |
| ProceedsFromStockOptionExercised | 558.00 | 0.00 | 28.88K | 31.70K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 12.07M | 1.59M | 0.00 | 18.86M |
| CommonStockIssuance | 12.07M | 1.59M | 0.00 | 18.86M |
| NetIssuancePaymentsOfDebt | -4.81K | -4.81K | -801.00 | 4.20M |
| NetLongTermDebtIssuance | -4.81K | -4.81K | -801.00 | 4.20M |
| LongTermDebtPayments | -2.00M | -4.81K | -801.00 | -298.62K |
| LongTermDebtIssuance | 2.00M | 0.00 | 0.00 | 4.50M |
| InvestingCashFlow | -306.78K | -704.17K | -1.20M | -23.95K |
| CashFlowFromContinuingInvestingActivities | -306.78K | -704.17K | -1.20M | -23.95K |
| NetPPEPurchaseAndSale | -306.78K | -704.17K | -1.20M | -23.95K |
| PurchaseOfPPE | -306.78K | -704.17K | -1.20M | -23.95K |
| OperatingCashFlow | -7.82M | -8.31M | -7.74M | -4.37M |
| CashFlowFromContinuingOperatingActivities | -7.82M | -8.31M | -7.74M | -4.37M |
| ChangeInWorkingCapital | -633.19K | 666.73K | 578.54K | -1.49M |
| ChangeInOtherWorkingCapital | 265.08K | |||
| ChangeInOtherCurrentAssets | -6.59K | 6.55K | -14.19K | -21.02K |
| ChangeInPayablesAndAccruedExpense | -1.04M | -266.04K | 633.50K | 2.59K |
| ChangeInAccruedExpense | -695.65K | -30.28K | 336.62K | 204.84K |
| ChangeInPayable | -346.35K | -235.76K | 296.88K | -202.25K |
| ChangeInAccountPayable | -346.35K | -235.76K | 298.88K | -79.15K |
| ChangeInPrepaidAssets | 150.32K | 926.22K | -40.77K | -1.55M |
| ChangeInInventory | 0.00 | 84.76K | ||
| ChangeInReceivables | 0.00 | |||
| ChangesInAccountReceivables | 0.00 | |||
| OtherNonCashItems | 308.62K | 1.30K | 222.01K | |
| StockBasedCompensation | 20.09K | 189.25K | 433.00K | 68.46K |
| AssetImpairmentCharge | 1.79K | 237.31K | 0.00 | |
| DepreciationAmortizationDepletion | 199.10K | 780.96K | 306.37K | 145.72K |
| DepreciationAndAmortization | 199.10K | 780.96K | 306.37K | 145.72K |
| Depreciation | 199.10K | 780.96K | 306.37K | 145.72K |
| OperatingGainsLosses | 3.41K | 1.79K | 137.00 | 170.66K |
| GainLossOnInvestmentSecurities | 170.66K | |||
| GainLossOnSaleOfPPE | 3.41K | 1.79K | 137.00 | 0.00 |
| NetIncomeFromContinuingOperations | -7.72M | -9.95M | -9.30M | -3.49M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BJDX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|